Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue (2021)

Amylyx Pharmaceuticals has reported Non-Current Deffered Revenue over the past 1 years, most recently at $35000.0 for Q4 2021.

  • Quarterly results put Non-Current Deffered Revenue at $35000.0 for Q4 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $35000.0 (changed N/A YoY), and the annual figure for FY2021 was $35000.0, changed.
  • Non-Current Deffered Revenue for Q4 2021 was $35000.0 at Amylyx Pharmaceuticals.
  • Over the last five years, Non-Current Deffered Revenue for AMLX hit a ceiling of $35000.0 in Q4 2021 and a floor of $35000.0 in Q4 2021.